Gilteritinib 40 Mg (gefitinib mechanism of action)-Gilternib

Gilteritinib (Gilternib) is used to treat adults with relapsed or refractory acute myeloid leukemia (AML) that has a specific FMS-like tyrosine kinase 3 (FLT3) mutation. This mutation must be confirmed by an FDA-approved test for the medication to be prescribed.